▟ Vinebot intrinsic value, daily

← back

CI Cigna

healthcare · valued with opus medium conviction · deep-dived 2026-10-13

STRONG BUY
Intrinsic value$359.39
Price (at call)$283.34
Margin of safety +26.8%
vs market (rating basis) +85.6%

Cash-rich PBM-plus-insurer priced for regulatory doom; modest growth still implies meaningful upside.

The story

Cigna is two businesses: Evernorth (Express Scripts PBM plus Accredo/CuraScript specialty pharmacy), which brings in most of the revenue on thin margins, and Cigna Healthcare, a commercial and employer-focused insurer with higher margins. Its moat is scale in drug purchasing and specialty distribution, but the PBM model faces political and regulatory pressure on rebates and spread pricing. Cigna's own move toward rebate-free pricing points to lower reported revenue and a lower margin ceiling. It is a mature, cash-generative business that buys back shares, with growth slowing toward the rate of healthcare spending.

I set growth below the 15% 5-year CAGR because that figure was inflated by the Centene and specialty contract wins; PBM reform and the shift to rebate-free pricing cap growth near healthcare spending. The 3.8% margin is the midpoint of the 2.7-5.4% history, not the 2022 peak, because PBM economics are compressing. Sales-to-capital stays near the current 3.8 because the asset-light PBM needs little capital. The baseline's 525 implies the stock is roughly 85% undervalued, which looks too promotional, so I trimmed growth and margin.

Value drivers

Revenue growth (Y1)4.0%
Terminal growth3.0%
Forecast horizon6y
Target operating margin3.8%
Years to target margin4
Sales-to-capital3.60
Beta0.85
Failure probability2.0%
Cost of capital (WACC)8.1%
Terminal WACC8.5%

Valuation bridge

PV of explicit FCFF30.39B
PV of terminal value90.52B
Equity value94.97B
÷ shares → per share$359.39

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 292.59B 4.0% 3.6% 8.59B 3.13B 5.46B 5.05B
2 303.71B 3.8% 3.7% 9.05B 3.09B 5.96B 5.11B
3 314.64B 3.6% 3.7% 9.52B 3.04B 6.48B 5.14B
4 325.34B 3.4% 3.8% 9.99B 2.97B 7.02B 5.15B
5 335.75B 3.2% 3.8% 10.31B 2.89B 7.42B 5.03B
6 345.82B 3.0% 3.8% 10.62B 2.80B 7.82B 4.91B

Key risks

  • PBM reform (delinking, rebate pass-through, FTC action) compresses Evernorth margins
  • Loss or repricing of large PBM clients, such as Centene, on renewal
  • Medical cost trend inflation (GLP-1s, specialty drugs) squeezing Cigna Healthcare margins

Catalysts

  • Clarity on PBM legislation that removes the regulatory overhang
  • Specialty pharmacy and biosimilar growth plus continued large buybacks at roughly 11x earnings

History

DatePriceIntrinsicMoSRating
2026-10-13$283.34 $359.39 +26.8% STRONG BUY
2026-08-24$277.51 $613.68 +121.1% STRONG BUY
2026-07-02$277.07 $577.43 +108.4% STRONG BUY
2026-06-23$283.08 $587.81 +107.6% STRONG BUY